Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994 Mar;149(3 Pt 1):815-7
Date
03/01/1994Pubmed ID
8118654DOI
10.1164/ajrccm.149.3.8118654Scopus ID
2-s2.0-0028212309 (requires institutional sign-in at Scopus site) 55 CitationsAbstract
The incidence of disease caused by Mycobacterium tuberculosis (including drug-resistant strains) and M. avium complex (MAC) is increasing. Hypersensitivity reactions to antimycobacterial agents are relatively uncommon, but when they occur they may result in cessation of therapeutic medications. We report our experience with rapid oral desensitization to ethambutol and rifampin in a group of 10 patients with mycobacterial disease who had experienced cutaneous hypersensitivity reactions to these drugs. An adaptation of the rapid oral desensitization protocol for penicillin was used, with the dosing intervals increased to account for the different kinetics of these drugs. Adverse reactions were few and easily treated without necessitating cessation of therapy. We conclude that oral desensitization to rifampin and ethambutol by our protocol is safe and effective, allowing these patients to proceed with an optimal antimycobacterial regimen.
Author List
Matz J, Borish LC, Routes JM, Rosenwasser LJMESH terms used to index this publication - Major topics in bold
Administration, OralAged
Clinical Protocols
Desensitization, Immunologic
Drug Administration Schedule
Drug Eruptions
Ethambutol
Humans
Middle Aged
Mycobacterium Infections, Nontuberculous
Mycobacterium avium-intracellulare Infection
Rifampin